Galmed Pharmaceuticals (NASDAQ:GLMD) Issues Quarterly Earnings Results, Beats Expectations By $0.26 EPS

Posted by Geri Gentry on Sep 3rd, 2026

Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) issued its earnings results on Wednesday. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.12) by $0.26, FiscalAI reports.

Galmed Pharmaceuticals Stock Up 5.1%

Shares of NASDAQ:GLMD opened at $4.12 on Thursday. The company’s fifty day moving average is $4.42 and its two-hundred day moving average is $4.74. The company has a market cap of $4.28 million, a P/E ratio of -0.57 and a beta of 0.67. Galmed Pharmaceuticals has a 12-month low of $3.29 and a 12-month high of $13.20.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 76.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Check Out Our Latest Report on Galmed Pharmaceuticals

Galmed Pharmaceuticals Company Profile

(Get Free Report)

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.